Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Change in Cash (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Change in Cash for 7 consecutive years, with $32.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash rose 121.53% year-over-year to $32.4 million, compared with a TTM value of $162.7 million through Dec 2025, up 336.23%, and an annual FY2025 reading of $162.7 million, up 336.23% over the prior year.
  • Change in Cash was $32.4 million for Q4 2025 at Avidity Biosciences, down from $106.3 million in the prior quarter.
  • Across five years, Change in Cash topped out at $286.3 million in Q1 2024 and bottomed at -$221.7 million in Q1 2023.
  • Average Change in Cash over 5 years is $3.2 million, with a median of $4.1 million recorded in 2022.
  • The sharpest move saw Change in Cash skyrocketed 1281.79% in 2021, then crashed 796.21% in 2022.
  • Year by year, Change in Cash stood at -$89.6 million in 2021, then surged by 319.61% to $196.7 million in 2022, then crashed by 49.45% to $99.4 million in 2023, then crashed by 251.18% to -$150.3 million in 2024, then skyrocketed by 121.53% to $32.4 million in 2025.
  • Business Quant data shows Change in Cash for RNA at $32.4 million in Q4 2025, $106.3 million in Q3 2025, and -$10.3 million in Q2 2025.